Maintenance of efficacy after duodenal– jejunal bypass liner explantation in the first NHS EndoBarrier service

Authors

  • Robert EJ Ryder Sandwell & West Birmingham NHS Trust, City Hospital, Birmingham, UK
  • Mahi Yadagiri
  • Susan P Irwin
  • Wyn Burbridge
  • Hardeep Gandhi
  • Rachael A Allden
  • John P Bleasdale
  • Edward N Fogden
  • Mark R Anderson
  • Piya Sen Gupta

DOI:

https://doi.org/10.15277/bjd.2017.157

Keywords:

diabetes, obesity, diabesity, EndoBarrier, bariatric surgery

Abstract

EndoBarrier®, a 60 cm endoscopically implanted proximal intestinal liner, reduces weight and HbA1c over 1 year. We report the outcomes of the first 12 patients who completed 6 months post EndoBarrier removal in the first NHS EndoBarrier service. All patients were obese (body mass index 41.7±9.8 kg/m2) with diabetes for 10–25 years and 75% were on insulin therapy. All patients (age 52.4±9.3 years) were advised to institute behavioural changes during the implant period (1 year) and maintain them thereafter. Implantation of EndoBarrier for 1 year reduced weight (17.6±8.9 kg, p<0.001), HbA1c (26.7±20.8 mmol/mol, 2.4±1.9%, p=0.001), systolic blood pressure (14.1±16.1 mmHg, p=0.011) and median total daily insulin dose from 104 to 48 Units/day (p=0.024) (n=9). Six months post EndoBarrier removal, 75% of patients sustained the metabolic improvement achieved with EndoBarrier; insulin dose requirement continued to fall and four of the nine insulin-treated patients discontinued insulin. Of the three patients whose weight/glycaemic control worsened, two had depression and one became immobile after explantation due to ill health unrelated to EndoBarrier treatment. Most (93.8%) of our patients stated that they would be extremely likely to recommend our service to friends and family. These data are encouraging for wider establishment of NHS EndoBarrier services.

Author Biography

Robert EJ Ryder, Sandwell & West Birmingham NHS Trust, City Hospital, Birmingham, UK

Dr Bob Ryder
Chief investigator ABCD REVISE-Diabesity and End-OSA Studies with Endobarrier
Clinical lead, ABCD audits of new diabetes therapies
Consultant Diabetologist
City Hospital
Dudley Road
Birmingham B18 7QH

References

GI Dynamics. The EndoBarrier GI Liner with Delivery System: instructions for use. GID part number 50-10-00552 Rev N. http://gidynamics.com/wp-content/uploads/2017/09/50-10-00552-Rev-N-IFU-EB-GI-Liner-with-Delivery-System.pdf (accessed 20 September 2017)

de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal–jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 2013;23:1354–60. https://doi.org/10.1007/s11695-013-0921-3

Betzel B, Homan J, Aarts EO, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc 2017;31:2881–91. https://doi.org/10.1007/s00464-016-5299-6

Kaválková P, Mráz M, Trachta P, et al. Endocrine effects of duodenal– jejunal exclusion in obese patients with type 2 diabetes mellitus. J Endocrinol 2016;231:11–22. https://doi.org/10.1530/JOE-16-0206

Koehestanie P, Dogan K, Berends F, et al. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open 2014;2:E21–E27. https://doi.org/10.1055/s-0034-1365222.

Sen Gupta P, Drummond R, McGowan BM, et al. One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagonlike-peptide-1 (GLP-1) therapy: a randomised controlled trial. Diabetologia 2016;59(Suppl 1):S272, 569.

Sen Gupta P, Drummond R, McGowan BM, et al. One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagon-like peptide-1 (GLP-1) therapy: a randomised controlled trial. ePosters video presentation, European Association for the Study of Diabetes, Munich, 2016. http://m.easdvirtualmeeting.org/#ePostersVideo/29622/Player (accessed 19 September 2017)

Ryder REJ, Johal VS, Murphy HM, et al. The effect of 1-year’s endoscopic proximal intestinal exclusion using Endobarrier on 10-year cardiovascular risk in type 2 diabetes. Webcast of presentation at American Diabetes Association, Scientific Sessions, New Orleans, 2016. http://buff.ly/2d0OTaB (accessed 19 September 2017)

The UKPDS Risk Engine v2.0. Available at https://www.dtu.ox.ac.uk/riskengine/ (accessed 19 September 2017)

Examples of our Birmingham patients treated with Endobarrier. This file will be regularly updated with new examples into the future. http://www.diabetologists-abcd.org.uk/Endobarrier/Birmingham_Endobarrier_patients.pdf (accessed 19 September 2017)

Odom J, Zalesin OJ, KC, Washington TL, et al. Behavioural predictors of weight regain after bariatric surgery. Obes Surg 2010;20:349–56. https://doi.org/10.1007/s11695-009-9895-6.

Christou NV, Look D, MacLean LD. Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 2006;244:734–40. https://doi.org/10.1097/01.sla.0000217592. 04061.d5.

Downloads

Published

2018-03-16

Issue

Section

Learning from practice

Most read articles by the same author(s)

1 2 3 > >>